Darwin Wealth Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32.6K | Buy |
1,354
+4
| +0.3% | +$105 | 0.01% | 280 |
|
|
2026
Q1 | $37.9K | Buy |
1,350
+4
| +0.3% | +$106 | 0.01% | 243 |
|
|
2025
Q4 | $33.5K | Buy |
1,346
+4
| +0.3% | +$101 | 0.01% | 253 |
|
|
2025
Q3 | $34.2K | Buy |
1,342
+3
| +0.2% | +$74 | 0.01% | 244 |
|
|
2025
Q2 | $32.5K | Sell |
1,339
-205
| -13% | -$4.78K | 0.01% | 236 |
|
|
2025
Q1 | $41K | Hold |
1,544
| – | – | 0.01% | 241 |
|
|
2024
Q4 | $41K | Sell |
1,544
-1,574
| -50% | -$42.7K | 0.01% | 241 |
|
|
2024
Q3 | $90.2K | Buy |
+3,118
| New | +$91K | 0.02% | 193 |
|
|
2023
Q2 | – | Sell |
-5,179
| Closed | -$213K | – | 160 |
|
|
2023
Q1 | $213K | Sell |
5,179
-517
| -9% | -$22.3K | 0.06% | 149 |
|
|
2022
Q4 | $273K | Sell |
5,696
-172
| -3% | -$8.25K | 0.07% | 143 |
|
|
2022
Q3 | $256K | Sell |
5,868
-531
| -8% | -$25.8K | 0.06% | 136 |
|
|
2022
Q2 | $318K | Buy |
6,399
+120
| +2% | +$6.12K | 0.06% | 134 |
|
|
2022
Q1 | $325K | Sell |
6,279
-231
| -4% | -$12K | 0.05% | 141 |
|
|
2021
Q4 | $352K | Sell |
6,510
-281
| -4% | -$13.9K | 0.06% | 139 |
|
|
2021
Q3 | $292K | Sell |
6,791
-4,708
| -41% | -$209K | 0.05% | 143 |
|
|
2021
Q2 | $450K | Buy |
11,499
+303
| +3% | +$11.8K | 0.07% | 120 |
|
|
2021
Q1 | $405K | Sell |
11,196
-354
| -3% | -$12.6K | 0.07% | 121 |
|
|
2020
Q4 | $425K | Buy |
11,550
+72
| +0.6% | +$2.64K | 0.08% | 115 |
|
|
2020
Q3 | $399K | Sell |
11,478
-3,816
| -25% | -$134K | 0.09% | 113 |
|
|
2020
Q2 | $474K | Sell |
15,294
-5,842
| -28% | -$198K | 0.12% | 104 |
|
|
2020
Q1 | $654K | Sell |
21,136
-42,654
| -67% | -$1.45M | 0.21% | 75 |
|
|
2019
Q4 | $2.37M | Buy |
63,790
+2,690
| +4% | +$95.8K | 0.63% | 66 |
|
|
2019
Q3 | $2.08M | Buy |
61,100
+2,067
| +4% | +$75.2K | 0.62% | 61 |
|
|
2019
Q2 | $2.43M | Buy |
59,033
+996
| +2% | +$39.5K | 0.75% | 61 |
|
|
2019
Q1 | $2.34M | Buy |
58,037
+1,896
| +3% | +$75.9K | 0.77% | 51 |
|
|
2018
Q4 | $2.32M | Buy |
56,141
+612
| +1% | +$25.4K | 1.62% | 21 |
|
|
2018
Q3 | $2.32M | Buy |
55,529
+7,803
| +16% | +$300K | 1.3% | 24 |
|
|
2018
Q2 | $1.65M | Buy |
47,726
+8,606
| +22% | +$294K | 1.07% | 27 |
|
|
2018
Q1 | $1.31M | Buy |
39,120
+4,271
| +12% | +$147K | 0.95% | 28 |
|
|
2017
Q4 | $1.2M | Buy |
34,849
+6,973
| +25% | +$238K | 0.51% | 71 |
|
|
2017
Q3 | $944K | Buy |
27,876
+5,407
| +24% | +$174K | 0.91% | 28 |
|
|
2017
Q2 | $716K | Buy |
22,469
+8,497
| +61% | +$268K | 0.4% | 75 |
|
|
2017
Q1 | $453K | Buy |
13,972
+3,167
| +29% | +$99.9K | 0.26% | 84 |
|
|
2016
Q4 | $333K | Buy |
10,805
+505
| +5% | +$15.4K | 0.22% | 81 |
|
|
2016
Q3 | $331K | Sell |
10,300
-4,341
| -30% | -$145K | 0.26% | 67 |
|
|
2016
Q2 | $489K | Buy |
+14,641
| New | +$467K | 0.42% | 62 |
|
Other funds holding PFE
Darwin Wealth Management's PFE Position: Q2 2026 in Review
Darwin Wealth Management increased its Pfizer (PFE) stake by 0.3% in Q2 2026, buying an estimated $105 and bringing the position to 1,354 shares worth $32.6K. The position accounts for 0.01% of the portfolio, ranked #280.
Darwin Wealth Management first reported a position in PFE in Q2 2016 and has held it in 36 quarters since. The position peaked at $2.43M in Q2 2019. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Darwin Wealth Management held 1,354 shares of Pfizer worth $32.6K as of Q2 2026.
- Darwin Wealth Management bought 4 Pfizer shares in Q2 2026, an estimated $105.
- Pfizer made up 0.01% of Darwin Wealth Management's portfolio in Q2 2026, its #280 holding.
- Darwin Wealth Management first reported a position in Pfizer in Q2 2016 and has held it in 36 quarters since.
- Darwin Wealth Management's Pfizer position peaked at $2.43M in Q2 2019.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Darwin Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.